Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00006436 · OUTCOME

Number of Cycles of Hematologic Toxicity

EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection · Source last updated 2026-08-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
cycles
Interval / dispersion
Not reported
Time frame
Up to 112 cycles (each cycle is 21 days + 7 days window)

What was measured

Cumulative number of cycles of hematologic toxicity. Hematologic (i.e., decrease in bone marrow and blood cells) toxicity was assessed by the Common Toxicity Criteria (CTC v2.0).

Analysis population: One participant declined to participate before treatment started.

Groups in this outcome

Arm 1-Combination Chemo and Biological Therapy

Combination chemo and biological therapy Rituximab: 2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5 Filgrastim: Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle Etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin hydrochloride (EPOCH): combination chemotherapy: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm 1-Combination Chemo and Biological Therapy67

Reported measurements

Febrile neutropenia
Values in cycles · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 1-Combination Chemo and Biological Therapy25Not reportedNot reportedNot reportedNot reported
Neutropenia with a Nadir <500 cells/mm^3
Values in cycles · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 1-Combination Chemo and Biological Therapy112Not reportedNot reportedNot reportedNot reported
Neutropenia with a Nadir <100 cells/mm^3
Values in cycles · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 1-Combination Chemo and Biological Therapy77Not reportedNot reportedNot reportedNot reported
Thrombocytopenia with a Nadir <50,000 platelets/mm^3
Values in cycles · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 1-Combination Chemo and Biological Therapy40Not reportedNot reportedNot reportedNot reported
Thrombocytopenia with a Nadir <25,000 platelets/mm^3
Values in cycles · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 1-Combination Chemo and Biological Therapy6Not reportedNot reportedNot reportedNot reported
Anemia: hemoglobin <8 g/dL
Values in cycles · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 1-Combination Chemo and Biological Therapy36Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        25
    title
    Febrile neutropenia
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        112
    title
    Neutropenia with a Nadir <500 cells/mm^3
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        77
    title
    Neutropenia with a Nadir <100 cells/mm^3
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        40
    title
    Thrombocytopenia with a Nadir <50,000 platelets/mm^3
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        6
    title
    Thrombocytopenia with a Nadir <25,000 platelets/mm^3
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        36
    title
    Anemia: hemoglobin <8 g/dL
denoms
  1. counts
    1. group Id
      OG000
      value
      67
    units
    Participants
description
Cumulative number of cycles of hematologic toxicity. Hematologic (i.e., decrease in bone marrow and blood cells) toxicity was assessed by the Common Toxicity Criteria (CTC v2.0).
groups
  1. description
    Combination chemo and biological therapy Rituximab: 2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5 Filgrastim: Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle Etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin hydrochloride (EPOCH): combination chemotherapy: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles
    id
    OG000
    title
    Arm 1-Combination Chemo and Biological Therapy
param Type
NUMBER
population Description
One participant declined to participate before treatment started.
reporting Status
POSTED
time Frame
Up to 112 cycles (each cycle is 21 days + 7 days window)
title
Number of Cycles of Hematologic Toxicity
type
SECONDARY
unit Of Measure
cycles

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice